Effectiveness and cost-effectiveness of interferon beta and glatiramer acetate in the UK Multiple Sclerosis Risk Sharing Scheme at 6 years: a clinical cohort study with natural history comparator
- 1 May 2015
- journal article
- research article
- Published by Elsevier in The Lancet Neurology
- Vol. 14 (5) , 497-505
Abstract
No abstract availableKeywords
Funding Information
- Health Technology Assessment Programme (10/55/01)
- National Multiple Sclerosis Society
- Canadian Institutes of Health Research
- MS Canada
This publication has 29 references indexed in Scilit:
- Temporal trends of disability progression in multiple sclerosis: findings from British Columbia, Canada (1975–2009)Multiple Sclerosis Journal, 2011
- Cost-effectiveness of disease-modifying therapy for multiple sclerosisNeurology, 2011
- Assessing changes in relapse rates in multiple sclerosisMultiple Sclerosis Journal, 2010
- Multiple sclerosis risk sharing scheme: two year results of clinical cohort study with historical comparatorBMJ, 2009
- Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trialsBritish Journal of Clinical Pharmacology, 2008
- Immortal time bias in the study of effectiveness of interferon‐β in multiple sclerosisAnnals of Neurology, 2008
- Measurement of long-term outcomes in observational and randomised controlled trialsThe British Journal of Psychiatry, 2007
- Immunomodulatory drugs for multiple sclerosis: a systematic review of clinical and cost effectivenessExpert Opinion on Pharmacotherapy, 2001
- Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosisNeurology, 1995
- Rating neurologic impairment in multiple sclerosisNeurology, 1983